Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...
Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.
Lipella Pharmaceuticals LIPO shares increased by 158.9% to $6.68 during Thursday's pre-market session. The market value of their outstanding shares is at $8.0 million. MBX Biosciences MBX stock moved ...
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results ...
CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase ...
Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement ...
In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at just $0.34. According to InvestingPro data, the company maintains a strong ...